miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Sorafenib
extracellular vesicle
hepatocellular carcinoma
liquid biopsy
miRNA
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
28 08 2022
28 08 2022
Historique:
received:
25
07
2022
revised:
21
08
2022
accepted:
26
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
Sorafenib constitutes a suitable treatment alternative for patients with advanced hepatocellular carcinoma (HCC) in whom atezolizumab + bevacizumab therapy is contraindicated. The aim of the study was the identification of a miRNA signature in liquid biopsy related to sorafenib response. miRNAs were profiled in hepatoblastoma HepG2 cells and tested in animal models, extracellular vesicles (EVs), and plasma from HCC patients. Sorafenib altered the expression of 11 miRNAs in HepG2 cells. miR-200c-3p and miR-27a-3p exerted an anti-tumoral activity by decreasing cell migration and invasion, whereas miR-122-5p, miR-148b-3p, miR-194-5p, miR-222-5p, and miR-512-3p exerted pro-tumoral properties by increasing cell proliferation, migration, or invasion, or decreasing apoptosis. Sorafenib induced a change in EVs population with an increased number of larger EVs, and promoted an accumulation of miR-27a-3p, miR-122-5p, miR-148b-3p, miR-193b-3p, miR-194-5p, miR-200c-3p, and miR-375 into exosomes. In HCC patients, circulating miR-200c-3p baseline levels were associated with increased survival, whereas high levels of miR-222-5p and miR-512-3p after 1 month of sorafenib treatment were related to poor prognosis. The RNA sequencing revealed that miR-200c-3p was related to the regulation of cell growth and death, whereas miR-222-5p and miR-512-3p were related to metabolic control. The study showed that Sorafenib regulates a specific miRNA signature in which miR-200c-3p, miR-222-5p, and miR-512-3p bear prognostic value and contribute to treatment response.
Sections du résumé
BACKGROUND
Sorafenib constitutes a suitable treatment alternative for patients with advanced hepatocellular carcinoma (HCC) in whom atezolizumab + bevacizumab therapy is contraindicated. The aim of the study was the identification of a miRNA signature in liquid biopsy related to sorafenib response.
METHODS
miRNAs were profiled in hepatoblastoma HepG2 cells and tested in animal models, extracellular vesicles (EVs), and plasma from HCC patients.
RESULTS
Sorafenib altered the expression of 11 miRNAs in HepG2 cells. miR-200c-3p and miR-27a-3p exerted an anti-tumoral activity by decreasing cell migration and invasion, whereas miR-122-5p, miR-148b-3p, miR-194-5p, miR-222-5p, and miR-512-3p exerted pro-tumoral properties by increasing cell proliferation, migration, or invasion, or decreasing apoptosis. Sorafenib induced a change in EVs population with an increased number of larger EVs, and promoted an accumulation of miR-27a-3p, miR-122-5p, miR-148b-3p, miR-193b-3p, miR-194-5p, miR-200c-3p, and miR-375 into exosomes. In HCC patients, circulating miR-200c-3p baseline levels were associated with increased survival, whereas high levels of miR-222-5p and miR-512-3p after 1 month of sorafenib treatment were related to poor prognosis. The RNA sequencing revealed that miR-200c-3p was related to the regulation of cell growth and death, whereas miR-222-5p and miR-512-3p were related to metabolic control.
CONCLUSIONS
The study showed that Sorafenib regulates a specific miRNA signature in which miR-200c-3p, miR-222-5p, and miR-512-3p bear prognostic value and contribute to treatment response.
Identifiants
pubmed: 36078082
pii: cells11172673
doi: 10.3390/cells11172673
pmc: PMC9454520
pii:
doi:
Substances chimiques
Biomarkers
0
MIRN200 microRNA, human
0
MIRN222 microRNA, human
0
MIRN512 microRNA, human
0
MicroRNAs
0
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Oncol Lett. 2020 Aug;20(2):1727-1733
pubmed: 32724415
Oncotarget. 2017 Apr 18;8(34):57707-57722
pubmed: 28915706
Cancer Res. 2020 Apr 15;80(8):1720-1734
pubmed: 32015093
Am J Pathol. 2018 Mar;188(3):785-794
pubmed: 29248455
Cancer Cell Int. 2018 Jan 03;18:2
pubmed: 29308051
Int J Cancer. 2020 Feb 15;146(4):1052-1063
pubmed: 31259424
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Oncogene. 2017 Feb 2;36(5):667-677
pubmed: 27375021
Am J Transl Res. 2022 Jun 15;14(6):3610-3637
pubmed: 35836899
J Hepatol. 2022 Mar;76(3):652-664
pubmed: 34793870
Carcinogenesis. 2012 May;33(5):1113-20
pubmed: 22362728
Cell Death Discov. 2021 Dec 14;7(1):387
pubmed: 34907204
Cell Death Dis. 2021 Nov 12;12(11):1076
pubmed: 34772924
J Hepatol. 2020 Feb;72(2):250-261
pubmed: 31954490
J Hepatol. 2021 Oct;75(4):960-974
pubmed: 34256065
Hum Pathol. 2009 Oct;40(10):1512-5
pubmed: 19751877
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Br J Cancer. 2004 Jun 14;90(12):2390-6
pubmed: 15150555
J Exp Clin Cancer Res. 2016 Sep 30;35(1):159
pubmed: 27716356
Onco Targets Ther. 2020 Mar 09;13:2021-2030
pubmed: 32210570
Front Cell Dev Biol. 2021 Dec 23;9:797102
pubmed: 35004693
Cells. 2020 Jun 01;9(6):
pubmed: 32492896
Genome Biol. 2014;15(12):550
pubmed: 25516281
Life Sci. 2016 Jul 1;156:47-56
pubmed: 27174168
Gastroenterology. 2019 May;156(6):1731-1741
pubmed: 30738047
Oncotarget. 2014 Nov 30;5(22):11103-20
pubmed: 25333265
Biomedicines. 2021 Jul 13;9(7):
pubmed: 34356875
Oncogene. 2010 Apr 15;29(15):2228-37
pubmed: 20101231
Methods Mol Biol. 2006;320:283-93
pubmed: 16719400
Clin Cancer Res. 2012 Apr 15;18(8):2290-300
pubmed: 22374331
Gastroenterology. 2009 Jul;137(1):110-8
pubmed: 19362088
Biology (Basel). 2022 Feb 22;11(3):
pubmed: 35336722
J Cell Physiol. 2018 Jan;234(1):692-708
pubmed: 30132846
Oncotarget. 2017 Aug 10;8(42):72652-72665
pubmed: 29069816
Int J Biol Sci. 2022 Jan 1;18(2):637-651
pubmed: 35002514
J Proteome Res. 2020 Mar 6;19(3):1298-1309
pubmed: 31994402
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Hepatology. 2016 Aug;64(2):488-500
pubmed: 27015352
Front Genet. 2022 Apr 12;13:825261
pubmed: 35495130
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Environ Toxicol. 2022 Apr;37(4):683-694
pubmed: 34862716
Cells. 2021 Jul 27;10(8):
pubmed: 34440674
Clin Cancer Res. 2010 Feb 1;16(3):867-75
pubmed: 20103675
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Cell Death Dis. 2021 May 28;12(6):555
pubmed: 34050139
PeerJ. 2021 Apr 13;9:e11200
pubmed: 33954040
J Biochem Mol Toxicol. 2021 Jun;35(6):1-11
pubmed: 33760324
Genes (Basel). 2022 May 13;13(5):
pubmed: 35627262
BMC Med. 2009 Aug 24;7:41
pubmed: 19698189
Dis Markers. 2020 Jul 11;2020:3231273
pubmed: 32733617
BMC Mol Cell Biol. 2020 Jun 29;21(1):48
pubmed: 32600257
Oncogene. 2012 Jul 12;31(28):3357-69
pubmed: 22056881
Clin Cancer Res. 2017 Jul 15;23(14):3953-3965
pubmed: 28096271
Gut. 2020 Nov;69(11):2025-2034
pubmed: 32883873
Mol Cancer. 2011 May 15;10:52
pubmed: 21575166
Oncogene. 2009 Oct 8;28(40):3526-36
pubmed: 19617899
Int J Oncol. 2014 Oct;45(4):1537-46
pubmed: 25096647
Emerg Microbes Infect. 2022 Dec;11(1):616-628
pubmed: 35109781
FEBS Open Bio. 2016 Mar 10;6(4):326-37
pubmed: 27239445
Int J Mol Sci. 2019 Jun 14;20(12):
pubmed: 31207892
Liver Int. 2019 Dec;39(12):2214-2229
pubmed: 31436873
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Redox Biol. 2020 Jul;34:101528
pubmed: 32388267
PLoS One. 2022 Apr 28;17(4):e0267117
pubmed: 35482720